Medicamentsen-ligne vous propose les traitements dont vous avez besoin afin de prendre soin de votre santé sexuelle. Avec plus de 7 ans d'expérience et plus de 90.000 clients francophones, nous étions la première clinique fournissant du acheter cialis original en France à vente en ligne et le premier vendeur en ligne de Kamagra dans le monde. Pourquoi prendre des risques si vous pouvez être sûr avec Medicamentsen-ligne - Le service auquel vous pouvez faire confiance.

Ca_sturm_publikationen

Dissertation

Sturm A (1995). Stellenwert von Troponin-T in der Diagnostik akuter Abstoßungsreaktionen
nach Herztransplantation (Medizinische Fakultät der RWTH Aachen
Habilitation
Sturm A
(2004). Modulation intestinaler Wundheilungsvorgänge und Erhaltung der
mukosalen Immunhomöostase – eine Untersuchung zur Regulation der intestinalen Barriere
(Charité-Universitätsmedizin Berlin)
Originalarbeiten in Erst- oder Letztautorenschaft

1.
Sturm A, Layer P, Sudermann T, Goebell H. Hyberbilirubinämie bis zu 38 mg/dl bei
einer jungen Patientin mit Walshe-Tygstrup-Summerskill-Syndrom. Med Klin 1996; 91:
771-775
Sturm A, v.d. Ohe M, Rosien U, Goebell H, Layer P. Therapie einer radiogenen
Gastroparese mit Erythromycin. Dtsch Med Wschr 1996; 121: 402-405
Sturm A, Becker A, Goebell H, Dignass AU. Lysophosphatidic acid modulates
Intestinal Epithelial Cell Function. Ann N Y Acad Sci 1998; 859: 223-226
Sturm A, Sudermann T, Schulte KM, Goebell H, Dignass AU. A. Modulation of
intestinal epithelial wound healing in-vitro and in-vivo by lysophosphatidic acid.
Gastroenterology 1999; 117: 368-377
Sturm A, Holtmann G, Goebell H, Gerken G. Prokinetics in Patients with
Gastroparesis: A systematic analysis. Digestion 1999; 60: 422-427
Sturm A, Schulte C, Schatton R, Becker A, Cario E, Goebell H, Dignass AU.
Transforming growth factor-beta and hepatocyte growth factor plasma levels in patients
with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2000; 12: 445-450
Sturm A, Noppeney R, Reimer J, Ross B, Baumgart D, Sudermann T, Sadony V,
Gerken G. AIDS und Non-Hodgkin Lymphome – Kardiale Erstmanifestation eines
hochmalignen B-Zellymphoms nach 18 Jahren HIV-Infektion. Dtsch Med Wschr
2001;126: 364-366
Sturm A, Mohr S, Fiocchi C. Critical Role of Caspases in the Differential Regulation
of Apoptosis and Proliferation of Mucosal and Peripheral T-Cells. Gastroenterology
2002; 122: 1334-1345
Sturm A, Itoh J, Jacobberger J, Fiocchi C. p53 negatively regulates intestinal immunity
by delaying mucosal T cell cycling. J Clin Invest 2002; 109: 1481-1492

10. Sturm A, Zeeh J, Sudermann T, Rath H, Gerken G, Dignass AU. Lisofylline and
Lysophospholipids ameliorate experimental Colitis in Rats. Digestion 2002; 66: 23-29
11. Sturm A, Krivacic K, Fiocchi C, Levine AD. Dual Function of the Extracellular Matrix:
Stimulatory for Cell Cycle Progression of Naive T cells and Anti-Apoptotic for Memory T Cells. J Immunol 2004; 173: 3889-3900 12. Sturm A, Lensch M, André S, Kaltner H, Wiedenmann B, Rosewicz S, Dignass AU,
Gabius H.-J. Human Galectin-2: Novel Inducer of T-Cell Apoptosis with Distinct Profile of Caspase Activation. J Immunol 2004; 173: 3825-3837
13. Sturm A, Leite AZ, Danese S, Krivacic KA, West G, Mohr S, Jacobberger J, Fiocchi C.
Divergent cell cycle kinetics underlie the distinct functional capacity of mucosal T-cells in Crohn’s disease and ulcerative colitis. Gut 2004; 53: 1624-1631
14. Sturm A, Baumgart D, Harder’de-Heureuse J, Hotz A, Wiedenmann B, Dignass AU.
CXCL8 (Interleukin-8) modulates human intestinal epithelial cells through a CXCR1 dependent pathway. Cytokine 2005; 29: 42-48
15. Sturm A, Rilling K, Baumgart DC, Gargas K, Abou-Ghazalé T, Raupach B, Eckert J,
Schumann RR, Enders C, Sonnenborn U, Wiedenmann B, Dignass AU. Escherichia coli Nissle distinctively modulates T Cell Cycling and Expansion via Toll-Like Receptor 2 Signaling. Infect Immunity 2005; 73: 1452-1465
16. Grabig A, Paclik D, Guzy C, Dankof A, Baumgart DC, Erckenbrecht J, Raupach B,
Sonnenborn U, Eckert J, Schumann RR, Wiedenmann B, Dignass AU, Sturm A.
Escherichia coli strain Nissle 1917 ameliorates experimental colitis via Toll-like
Receptor-2 and Toll-like Receptor-4 dependent pathways. Infect Immunity 2006; 74:
4075-82

17. Grabig A, Veltzke-Schlieker W, Sturm A. Acute pancreatitis and duodenobiliary fistula–
a rare complication of Crohn’s disease. Dtsch Med Wochenschr. 2007; 132: 1264-7 18. Berndt U, Bartsch S, Philipsen L, Danese S, Wiedenmann B, Dignass AU, Hämmerle M, Sturm A. Proteomic analysis of the inflamed intestinal mucosa reveals distinctive
immune response profiles in Crohn’s disease and ulcerative colitis. J Immunol. 2007;
179: 295-304

19. Berndt U, Philipsen L, Bartsch S, Wiedenmann B, Baumgart DC, Hämmerle M, Sturm
A. Systematic High-Content Proteomic Analysis reveals substantial immunological
changes in colorectal cancer. Cancer Research 2008; 68: 880-888

20. Paclik D, Lohse K, Wiedenmann B, Dignass AU, Sturm A. Galectin-2 and -4, but not
Galectin-1, promote intestinal epithelial wound healing in vitro through a TGF-beta-independent mechanism. Inflamm Bowel Dis. 2008; 14: 1366-72
21. Guzy C, Paclik D, Schirbel A, Sonnenborn U, Wiedenmann A, Sturm A. The probiotic
Escherichia coli strain Nissle 1917 induces γδ T cell apoptosis via caspase- and FasL-dependent pathways. Int Immunol. 2008 Jul;20(7):829-40
22. Paclik D, Berndt U, Danese S, Wiedenmann B, Dignass AU, Sturm A. Galectin-4
contols intestinal inflammation by selective regulation of peripheral and mucosal T cell apoptosis and cell cycle. PLOS One, 2008; 3: e2629 23. Paclik D, Berndt U, Guzy C, Dankof A, Danese S, Holzloehner P, Rosewicz S, Wiedenmann B, Wittig BM, Dignass AU, Sturm A. Galectin-2 induces apoptosis of
lamina propria T lymphocytes and ameliorates acute and chronic experimental colitis in
mice. J Mol Med. 2008; 86: 1395-406

24. Guzy C, Schirbel A, Paclik D, Wiedenmann B, Dignass A, Sturm A. Enteral and
parenteral nutrition distinctively modulate intestinal permeability and T cell function in-vitro. European Journal of Nutrition Eur J Nutr. 2009; 48: 12-21 25. Schirbel A, Reichert A, Roll S, Baumgart DC, Buening C, Wittig B, Wiedenmann B, Dignass A, Sturm A. Impact of pain on health-related quality of life in patients with
inflammatory bowel disease. World J Gastroenterol. 2010; 16: 3168-77
26. Berndt U, Philipsen L, Bartsch S, Hu Y, Roecken C, Wiedenmann B, Haemmerle M, Roesch T, Sturm A. Comparative Multi-Epitope-Ligand-Cartography reveals essential
immunological alterations in Barrett's metaplasia and esophageal adenocarcinoma.
Molecular Cancer 2010; 9:177

27. Paclik D, Werner L, Guckelberger O, Wiedenmann B, Sturm A. Galectins distinctively
regulate central monocyte and macrophage function. Cellular Immunology 2011; 271: 97-103
28. Werner L, Paclik D, Fritz C, Reinhold D, Roggenbuck D, Sturm A. Identification of
pancreatic glycoprotein 2 as an endogenous immunomodulator of innate and adaptive immune responses. J Immunol. 2012; 189: 2774-83
29. Werner L, Berndt U, Paclik D, Danese S, Schirbel A, Sturm A. TNFα inhibitors restrict
T cell activation and cycling via Notch-1 signalling in inflammatory bowel disease. Gut 2012; 61: 1016-27
Originalarbeiten in Koautorenschaft:

1.
Dignass AU, Sturm A, Hotz A, Becker A, Goebell H. Interferon-γ modulates
intestinal epithelial cell function by a TGF-ß – independent pathway. Z Gastroenterol
1998; Suppl. 1: 50-57
Cario E, Becker A, Sturm A, Goebell H, Dignass AU. Peripheral blood mononuclear
cells promote intestinal epithelial restitution in vitro through an interleukin-
2/interferon-gamma-dependent pathway. Scand J Gastroenterol 1999; 34: 1132-
1138
Cario E, Jung S, Harder de-Heureuse J, Schulte C, Sturm A, Wiedenmann B,
Goebell H, Dignass AU. Effects of exogenous zinc supplementation on intestinal
epithelial repair in vitro. Eur J Clin Invest 2000; 30: 419-428
Danese S, de la Motte C, Sturm A, Vogel JD, West GA, Strong SA, Katz JA, Fiocchi
C. Platelets Trigger a CD40-dependent Inflammatory Response in the
Microvasculature of Inflammatory Bowel Disease Patients. Gastroenterology 2003;
124: 1249-1264
Baumgart DC, Metzke D, Schmitz J, Scheffold A, Sturm A, Wiedenmann B, Dignass
AU. Patients with active inflammatory bowel disease lack immature peripheral blood
plasmacytoid and myeloid dendritic cells. Gut 2005; 54: 228-36
Musso A, Dentelli P, Carlino A, Chiusa L, Repici A, Sturm A, Fiocchi C, Pizzetto M,
Pegoraro L, Sategna-Guidetti C, Brizzi MF. Signal Transducers and Activators of
Transcription 3 Signaling Pathway: An Essential Mediator of Inflammatory Bowel
Disease and Other Forms of Intestinal Inflammation. Inflamm Bowel Dis 2005; 11: 91-
98
Baumgart DC, Vierziger K, Sturm A, Wiedenmann B, Dignass AU. Mesalamine
promotes intestinal epithelial wound healing in vitro through a TGF-beta-independent
mechanism. Scand J Gastroenterol 2005; 8: 958-964
Baumgart DC, Sturm A, Wiedenmann B, Dignass AU. Uneventful pregnancy and
neonatal outcome with tacrolimus in refractory ulcerative colitis. Gut 2005; 40: 958-964
Baumgart DC, Pintoffl JP, Sturm A, Wiedenmann B, Dignass AU. Tacrolimus is safe
and effective in patients with severe steroid-refractory or steroid-dependent
inflammatory bowel disease - A long-term follow-up. Am J Gastroenterol. 2006; 101:
1048-56
10. Holtmann MH, Krummenauer F, Claas C, Kremeyer K, Lorenz D, Rainer O, Vogel I, Bocker U, Bohm S, Buning C, Duchmann R, Gerken G, Herfarth H, Lugering N, Kruis
W, Reinshagen M, Schmidt J, Stallmach A, Stein J, Sturm A, Galle PR, Hommes DW,
D'Haens G, Rutgeerts P, Neurath MF. Long-term effectiveness of azathioprine in IBD
beyond 4 years: a European multicenter study in 1176 patients. Dig Dis Sci.
2006;51:1516-24

11. Büning C, Schmidt HH, Molnar T, De Jong DJ, Fiedler T, Bühner S, Sturm A,
Baumgart DC, Nagy F, Lonovics J, Drenth JP, Landt O, Nickel R, Büttner J, Lochs H, Witt H. Heterozygosity for IL23R p.Arg381Gln confers a protective effect not only against Crohn’s disease but also ulcerative colitis. Aliment Pharmacol Ther. 2007; 26: 1025-33 12. Buning C, Durmus, Molnar, de Jong, Drenth JPH, Fiedler T, Gentz E, Todorov T, Haas V, Buhner S, Sturm A, Baumgart DC, Nagy F, Lonovics J, Landt O, Kage A, Buning H,
Nickel R, Buttner J, Lochs H, Schmidt HHJ, Witt H. A study in three European IBD
cohorts confirms that the ATG16L1 c.898A > G (p.Thr300Ala) variant is a susceptibility
factor for Crohn's disease. Journal of Crohn’ and Colitis 2007;1: 70-76
13. Büning C, Schmidt HH, Molnár T, Drenth JP, Fiedler T, Gentz E, Todorov T, Baumgart DC, Sturm A, Nagy F, Lonovics J, de Jong DJ, Landt O, Kage A, Nickel R, Büttner J,
Lochs H, Witt H. No association of the CARD8 (TUCAN) c.30T>A (p.C10X) variant with
Crohn’s disease: A study in 3 independent European cohorts. Inflamm Bowel Dis.
2008; 14: 332-337

14. Veterano S, Rescigno M, Rosaria Cera M, Corrreale M, Rumio C, Doni A, Fantini M,
Sturm A, Borroni E, Pepici A, locato M, Malesci A, Dejana E, Daneses S. Unique Role
of Junctional Adhesion Molecule-A in Maintaining Mucosal Homeostasis in
Inflammatory Bowel Disease. Gastroenterology 2008; 135: 173-84

15. Scaldaferri F, Vetrano S, Sans M, Arena V, Straface G, Stigliano E, Repici A, Sturm A,
Malesci A, Panes J, Yla-Herttuala S, Fiocchi C, Silvio D. VEGF-A Links Angiogenesis and Inflammation in Inflammatory Bowel Disease Pathogenesis. Gastroenterology 2009; 136: 585-95
16. Baumgart DC, Thomas S, Przesdzing I, Metzke D, Bielecki C, Lehmann SM, Lehnardt
S, Dörffel Y, Sturm A, Scheffold A, Schmitz J, Radbruch A. Exaggerated inflammatory
response of primary human myeloid dendritic cells to lipopolysaccharide in patients with
inflammatory bowel disease. Clin Exp Immunol. 2009;157: 423-36

17. Loser K, Sturm A, Voskort M, Kupas V, Balkow S, Auriemma M, Sternemann C,
Dignass AU, Luger TA, Beissert S Galectin-2 suppresses contact allergy by inducing apoptosis in activated CD8+ T cells. J Immunol. 2009;182: 5419-29 18. Baumgart DC, Thomas S, Przesdzing I, Metzke D, Bielecki C, Lehmann SM, Lehnardt S, Dörffel Y, Sturm A, Scheffold A, Schmitz J, Radbruch A. Exaggerated inflammatory
response of primary human myeloid dendritic cells to lipopolysaccharide in patients with
inflammatory bowel disease. Clin Exp Immunol. 2009; 157: 423-36
19. Holtmann MH, Krummenauer F, Claas C, Kremeyer K, Lorenz D, Rainer O, Vogel I, Böcker U, Böhm S, Büning C, Duchmann R, Gerken G, Herfarth H, Lügering N, Kruis
W, Reinshagen M, Schmidt J, Stallmach A, Stein J, Sturm A, Galle PR, Hommes DW,
D'Haens G, Rutgeerts P, Neurath MF. Significant Differences Between Crohn's
Disease and Ulcerative Colitis Regarding the Impact of Body Mass Index and Initial
Disease Activity on Responsiveness to Azathioprine: Results from a European
Multicenter Study in 1,176 Patients. Dig Dis Sci. 2010; 55:1066-78
20. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens G, Diamond RH, Broussard DL, Tang KL, van der Woude CJ, Rutgeerts P; SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010; 362: 1383-95
21. Van Assche G, Dignass A , Reinisch W, van der Woude CJ, Sturm A, De Vos M,
Guslandi M, Oldenburg B, Dotan I, Marteau P, Ardizzone A, Baumgart DC, D'Haens G, Gionchetti P, Portela F, Vucelic B, Soderholm J, Escher J, Koletzko S, Kolho KL, Lukas M, Mottet C, Tilg H, Vermeire S, Carbonnel F, Cole A, Novacek G, Reinshagen M, Tsianos E, Herrlinger K, Oldenburg B, Bouhnik Y, Kiesslich R, Stange E, Travis S, Lindsay J. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. Journal of Crohn’ and Colitis 2010;4:63-101
22. Rutella S, Vetrano , Correale C, Graziani C, Sturm A, Spinelli A, De Cristofaro R,
Repici A, Malesci A, Danese S. Enhanced platelet adhesion induces angiogenesis in intestinal inflammation and inflammatory bowel disease microvasculature. J Cell Mol Med. 2010; 15: 625-634 23. Chowers Y, Sturm A, Sans M, Papadakis K, Gazouli M, Harbord M, Jahnel J,
Mantzaris GJ, Meier J, Mottet C, Peyrin-Biroulet L, Allez M. Report of the ECCO workshop on anti-TNF therapy failures in inflammatory bowel diseases: biological roles and effects of TNF and TNF antagonists. J Crohns Colitis. 2010; 4: 367-76 24. Van Assche G, Dignass A, Reinisch W, van der Woude CJ, Sturm A, De Vos M,
Guslandi M, Oldenburg B, Dotan I, Marteau P, Ardizzone A, Baumgart DC, D'Haens G, Gionchetti P, Portela F, Vucelic B, Söderholm J, Escher J, Koletzko S, Kolho KL, Lukas M, Mottet C, Tilg H, Vermeire S, Carbonnel F, Cole A, Novacek G, Reinshagen M, Tsianos E, Herrlinger K, Oldenburg B, Bouhnik Y, Kiesslich R, Stange E, Travis S, Lindsay J. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. J Crohns Colitis. 2010; 4: 63-101
25. Teich N, Schmidt C, Stallmach A, Klugmann T, Vieth M, Baumgart DC, Sturm A,
Felten G, Hüppe D, Emmrich J, Böcker U, Maaser C, Bästlein EC, Ehehalt R, Krummenerl T, Bachmann O, Kruis W, Mroß M, Herrlinger K, Helwig U, Büning J, Aschenbeck J, Siegmund B, Preiß J, Maul J, Drossel R, Schiefke I, Reinshagen M, Heidemann J, Lügering A, Rehbehn KU, Pfeiffer A, Jessen P, Schreiber S, Rosezin B, Dignaß A, Böhm S, Bokemeyer B; German IBD Study Group. Adherence to the H1N1 vaccination recommendation in patients with Crohn's disease or ulcerative colitis. Dtsch Med Wochenschr. 2011;136: 939-943
26. Benckert J, Schmolka N, Kreschel C, Zoller MJ, Sturm A, Wiedenmann B, Wardemann
H. The majority of intestinal IgA+ and IgG+ plasmablasts in the human gut are antigen-specific. J Clin Invest. 2011;121: 1946-55 27. Hoffmann P, Sturm A, Stein J, Dignass AU. Interferon-γ modulates intestinal epithelial
cell function in-vitro through a TGFβ-dependent mechanism. Regul Pept. 2011; 168: 27-31
28. Roggenbuck D, Reinhold D, Wex, T, von Arnim U, Malfertheiner P, Sturm A, Werner
L, Bogdanos DP, Laass MW, Conrad K. Letter: Authors' response: antibodies to GP2, the major zymogen granule membrane glycoprotein, are specific for Crohn's disease and may reflect treatment response. Gut 2011; epub: 2 February 2011 29. Schmidt C, Dignass A, Hartmann F, Hüppe D, Kruis W, Layer P, Lüers A, Stallmach A, Teich N, Sturm A; IBD ahead. [IBD ahead 2010--Answering important questions in
Crohn's disease treatment]. Z Gastroenterol. 2011; 49: 1246-54
30. Herrlinger KR, Diculescu M, Fellermann K, Hartmann H, Howaldt S, Nikolov R, Petrov A, Reindl W, Otte JM, Stoynov S, Strauch U, Sturm A, Voiosu R, Ammendola A,
Dietrich B, Hentsch B, Stange EF. Efficacy, safety and tolerability of vidofludimus in
patients with inflammatory bowel disease: The ENTRANCE study. J Crohns Colitis.
2012 Oct 15i: 1873-9946
31. Sandborn WJ, Gasink C, Gao LL, Blank MA, Johanns J, Guzzo C, Sands BE, Hanauer SB, Targan S, Rutgeerts P, Ghosh S, de Villiers WJ, Panaccione R, Greenberg G, Schreiber S, Lichtiger S, Feagan BG; CERTIFI Study Group. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med. 2012; 367: 1519-28
32. Rutgeerts PJ, Fedorak RN, Hommes DW, Sturm A, Baumgart DC, Bressler B,
Schreiber S, Mansfield JC, Williams M, Tang M, Visich J, Wei X, Keir M, Luca D, Danilenko D, Egen J, O'Byrne S. A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis. Gut. 2012 Jun 20. [Epub ahead of print]
33. Wenger S, Nikolaus S, Howaldt S, Bokemeyer B, Sturm A, Preiss JC, Schoepfer AM,
Stallmach A, Schmidt C. Predictors for subsequent need for immunosuppressive therapy in early Crohn's disease. J Crohns Colitis. 2012; 6: 21-8 34. Grieser C, Denecke T, Steffen IG, Werner S, Kröncke T, Guckelberger O, Pape UF, Meier J, Thiel R, Kivelitz D, Sturm A, Hamm B, Röttgen R. Magnetic resonance
enteroclysis in patients with Crohn's disease: fat saturated T2-weighted sequences for
evaluation of inflammatory activity. J Crohns Colitis. 2012; 6: 294-301

35. Büning C, Geissler N, Prager M, Sturm A, Baumgart DC, Büttner J, Bühner S, Haas V,
Lochs H. Increased small intestinal permeability in ulcerative colitis: rather genetic
than environmental and a risk factor for extensive disease? Inflamm Bowel Dis. 2012;
18: 1932-9

36. Prager M, Büttner J, Haas V, Baumgart DC, Sturm A, Zeitz M, Büning C. The JAK2
variant rs10758669 in Crohn's disease: altering the intestinal barrier as one mechanism of action. Int J Colorectal Dis. 2012; 27: 565-73 37. Müller T, Beutler C, Picó AH, Otten M, Dürr A, Al-Abadi H, Guckelberger O, Meyer Zum Büschenfelde D, Jöhrens K, Volkmann M, Lankisch T, Voigtländer T, Anders M,
Shibolet O, Jefferson DM, Podolsky DK, Fischer A, Veltzke-Schlieker W, Adler A,
Baumgart DC, Sturm A, Wiedenmann B, Schott E, Berg T. Increased T-helper 2
cytokines in bile from patients with IgG4-related cholangitis disrupt the tight junction-
associated biliary epithelial cell barrier. Gastroenterology 2013; 144: 1116-28
38. Werner L, Sturm A, Roggenbuck D, Yahav L, Zion T, Meirowithz E, Ofer A, Guzner-
Gur H, Tulchinsky H, Dotan I. Antibodies against glycoprotein 2 are novel markers of intestinal inflammation in patients with an ileal pouch. J Crohns Colitis. 2013 Apr 29.: 1873-9946 39. Papay P, Ignjatovic A, Karmiris K, Amarante H, Milheller P, Feagan B, D'Haens G, Marteau P, Reinisch W, Sturm A, Steinwurz F, Egan L, Panés J, Louis E, Colombel JF,
Panaccione R. Optimising monitoring in the management of Crohn's disease: A
physician's perspective. J Crohns Colitis. 2013 Apr 3. doi:pii: S1873-9946(13)00070-6.
10.1016/j.crohns.2013.02.005. [Epub ahead of print]
40. Evstatiev R, Alexeeva O, Bokemeyer B, Chopey I, Felder M, Gudehus M, Iqbal T, Khalif I, Marteau P, Stein J, Gasche C; FERGI Study Group. Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013; 11: 269-77
Übersichtsarbeiten in Zeitschriften

1.
Sturm A, Holtmann G. Der Stellenwert von Sucralfat in der Eradikationstherapie von
Helicobacter pylorii. Z Gastroenterol 1997; 35: 1029-1030 (Impact-Factor = 1.188)
Sturm A, Layer P, Goebell H, Dignass AU. Short-Bowel Syndrome: An Update on
the Therapeutic Approach. Scand J Gastroenterol 1997; 32: 289-296 (Impact-Factor
= 2.084) (Anzahl der Zitate: 15)
Sturm A, Dignass AU. Klinische Relevanz von Phospholipiden im
Gastrointestinaltrakt. Dtsch Med Wschr 2000; 7: 192-198 (Impact-Factor = 0.590)
(Anzahl der Zitate: 2)
Dignass AU, Sturm A. Peptide growth factors in the intestine. Eur J Gastroenterol
Hepatol
2001; 13: 763-770 (Impact-Factor = 1.662) (Anzahl der Zitate: 62)
Sturm A, Fiocchi C. Life and death in the gut: more killing, less Crohn’s disease. Gut
2002; 51: 47-49 (Impact-Factor = 9.357) (Anzahl der Zitate: 15)
Sturm A, Dignass AU. Modulation of gastrointestinal wound repair and inflammation by
phospholipids. Biochim Biophys Acta - Molecular and Cell Biology of Lipids 2002, 1582:
282-288 (Impact-Factor = 4.357) (Anzahl der Zitate: 27)
Dignass AU, Baumgart DC, Sturm A. The aetiopathogenesis of inflammatory bowel
disease-immunology and repair mechanism. Aliment. Pharmacol Therapy 2004; 20: 9-
17 (Impact-Factor = 4.357) (Anzahl der Zitate: 19)
Sturm A. Einsatz von Probiotika und Würmern bei chronisch entzündlichen
Darmerkrankungen. Verdauungskrankheiten 2006; 24: 256-264
Sturm A, Dignass AU. Epithelial restitution and wound healing in inflammatory bowel
disease. World J Gastroenterol. 2008; 14: 348-53 (Impact-Factor = 2.092) (Anzahl der
Zitate: 18)

10. Sturm A, de Souza HS, Fiocchi C. Mucosal T cell proliferation and apoptosis in
inflammatory bowel disease. Curr Drug Targets. 2008; 9: 381-7 (Impact-Factor = 3.932) (Anzahl der Zitate: 6) 11. Sturm A. Der rationelle Einsatz von Probiotika. Verdauungskrankheiten 2008; 26: 198-

12. Sturm A. What Is the Role of Apoptosis in the Normal and Inflamed Intestine? Inflamm
Bowel Dis 2008; 14 (S2): 113-114 (Impact-Factor = 4.643) (Anzahl der Zitate: 0)
13. Meier J, Sturm A. Top-down versus Step-Up: new strategies in the treatment of
Crohn's disease. Z Gastroenterol. 2009; 47: 240-2 (Impact-Factor = 1.188) (Anzahl der Zitate: 0)
14. Meier J, Sturm A. The intestinal epithelial barrier: does it become impaired with age?
Dig Dis. 2009; 27: 240-5 (Impact-Factor = 1.838) (Anzahl der Zitate: 0)
15. Dignass AU, Hartmann F, Sturm A, Stein J. Management of inflammatory bowel
diseases during pregnancy. Dig Dis. 2009; 27: 341-6 (Impact-Factor = 1.838) (Anzahl der Zitate: 1) 16. Meier J, Sturm A. Concomitant Use of Immunomodulators with Anti-TNF in Crohn's
Disease: Yes or No? Curr Drug Targets. 2010, 11: 176-8 (Impact-Factor = 3.932) (Anzahl der Zitate: 0)
17. Chowers Y, Sturm A, Sans M, Papadakis K, Gazouli M, Harbord M, Jahnel J,
Mantzaris GJ, Meier J, Mottet C, Peyrin-Biroulet L, Allez M. Report of the ECCO workshop on anti-TNF therapy failures in inflammatory bowel diseases: biological roles and effects of TNF and TNF antagonists. J Crohns Colitis. 2010; 4: 367-76 (Impact-Factor = 1.8) 18. Travis SP, Higgins PD, Orchard T, Van Der Woude CJ, Panaccione R, Bitton A, O'Morain C, Panés J, Sturm A, Reinisch W, Kamm MA, D'Haens G. Review article:
defining remission in ulcerative colitis. Aliment Pharmacol Ther. 2011; 34: 113-24
19. Peyrin-Biroulet L, Ferrante M, Magro F, Campbell S, Franchimont D, Fidder H, Strid H, Ardizzone S, Veereman-Wauters G, Chevaux J-P, Allez M, Danese S, Sturm A. Impact
of mucosal healing on the course of inflammatory bowel disease – Results from the 2nd
Scientific workshop of the European Crohn’s and Colitis Organisation. J Crohns Colitis
2011; 5: 477-83

20. Meier J, Sturm A. Current treatment of ulcerative colitis. World J Gastroenterol. 2011;

21. Dignass A, Lindsay JO, Sturm A, Windsor A, Colombel JF, Allez M, D'Haens G,
D'Hoore A, Mantzaris G, Novacek G, Oresland T, Reinisch W, Sans M, Stange E, Vermeire S, Travis S, Van Assche G. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis. 2012; 6: 991-1030 22. Teich N, Helwig U, Pace A, Dignass AU, Hartmann F, Hüppe D, Schmidt C, Stallmach A, Sturm A, Kruis W, Layer P. [Rational and efficient diagnosis in different stages of
Crohn's disease]. Z Gastroenterol. 2012; 50: 684-93

23. Schirbel A, Sturm A. Imaging in inflammatory bowel disease mucosal healing in
ulcerative colitis: relevance for clinical outcomes. Curr Drug Targets. 2012; 13: 1234-44

Buchbeiträge:

Dignass AU, Sturm A, Podolsky DK. Epithelial injury and restitution. In: A.
Domschke, R. Stoll, T.A. Brasitus, M.F. Kagnoff (Ed.): Intestinal Mucosa and its
Diseases. Kluwer Academic Publisher, Dordrecht-Boston-London 1999: 293-299
Sturm A, Dignass AU. Chronisch entzündliche Darmerkrankungen bei HIV-
assoziiertem Immundefekt. In Brockmeyer N, Brodt B, Hoffmann K, Reimann G,
Stuecker M, Altmeyer P (Ed.): HIV-Infekt. Springer Verlag, Berlin, Heidelberg, New
York 1999: 442-450
Sturm A. Probiotika bei chronisch entzündlichen Darmerkrankungen. In A. Dignass,
J. Stein (Ed.): Chronisch entzündliche Darmerkrankungen. Springer Verlag, Berlin,
Heidelberg, New York 2002: 51-62
Vogel J, Sturm A, Fiocchi C. Specific Immunity in Inflammatory Bowel Disease. In:
A. Dignass, H. Lochs, E. Stange (Ed.): Trends and Controversies in Inflammatory
Bowel Disease. Kluwer Academic Publisher, Dordrecht-Boston-London 2004: 17-29
Sturm A, Dignass AU. Treatment of Skin Manifestations in Inflammatory Bowel
Disease. In: Dignass AU, Lochs H, Stange E (Ed.): Trends and Controversies in
Inflammatory Bowel Disease. Kluwer Academic Publisher, Dordrecht-Boston-London
2004: 225-235
Pape U.F., Sturm A, Wiedenmann B. Endokrin aktive Tumoren des
Gastrointestinaltraktes. In: Lehnert H, Werdan K (Ed.): Innere Medizin. Thieme,
Stuttgart, New York 2006: 61-69
Sturm A, Wiedenmann B. Erkrankungen des Dünndarms. In: Lehnert H, Werdan K
(Ed.): Innere Medizin. Thieme, Stuttgart, New York 2006: 180-192
Sturm A, Wiedenmann B. Chronisch-entzündliche Darmerkrankungen. In: Lehnert
H, Werdan K (Ed.): Innere Medizin. Thieme, Stuttgart, New York 2006: 193-204
Sturm A. Optimizing medical therapy in inflammatory bowel disease. In Balanzo J,
Ricart E. (Ed.): Enfermeded inflamatoria intestinal. Marge Medica books, Valencia
2006: 67-78

10. Sturm A, Fiocchi C. Cycling and death of lamina propria T lymphocytes in the normal
and inflamed gut mucosa. In Monteleone F (Ed.): Textbook of IBD. Landes Bioscience, Georgetown, im Druck

Source: http://www.krankenhaus-waldfriede.de/krankenhaus/docs/CA_INN_Publikationen.pdf

Listen_v23.xls

TESTED PRODUCT LIST - PREVOR FIRST EDITION : 15,03,95 EDITION N° 23 PRODUCTS TOXICITY CHARACTERISTICS DIPHOTERINE HEXAFLUORINE FLAMMABLE, HARMFUL, Dangerous to theenvironment1-PROPANAMINIUM,N,N,N-TRIMETHYL-3-[(1-OXO-2-PROPENYL)AMINO],CHLORIDE, POLYMER WITH 2-PROPENAMIDE 2-EHTG, dest, IBC WEISS KUPAL,950Kg 3D TRASAR 3DT134 30952 SYNTHOPON DAH94-505 ABSOLUE ALGUE

Microsoft word - 1.1.doc

Effective: 3/78 1.0 ABUSE Revised: 3/99, 1/05 Last Reviewed: 1/05 Adult Sexual Assault Victims General Information 1. Patients who are age 18 years or older are to be evaluated in the Adult Emergency 2. Patients age 17 years or less will be evaluated in the Pediatric ED. (See Policies and 3. Patients who are victims of sexual assault are a unique subset of ED patients.

Copyright © 2010-2014 Pharmacy Pills Pdf